Sidedness and addition of chemotherapy associated with treatment outcomes of regorafenib for metastatic colorectal cancer: a population-wide cohort study.

ABSTRACT:

Background

Regorafenib is a salvage option for metastatic colorectal cancer (mCRC). Understanding the prognostic factors for mCRC patients undergoing regorafenib treatment can help optimize therapeutic strategies.

Materials and methods

We searched Taiwan's National Health Insurance database for patients who began regorafenib treatment for mCRC between 1 September 2015 and 31 December 2018. Taiwan's National Death Registry and the Taiwan Cancer Registry were examined for data on survival and clinicopathological variables, respectively.

Results

In total, 3643 patients were included in the analysis. The median time to treatment discontinuation (TTD) was 2.3 months, and the median overall survival (OS) was 7.2 months. Compared with the patients with a right-sided tumor, t

SUBMITTER: Wu TC 

PROVIDER: S-EPMC12836779 | biostudies-literature | 2024 Jun

REPOSITORIES: biostudies-literature